Welcome, and thank you for your interest in gynaecological cancer research conducted by the Australia New Zealand Gynaecological Oncology Group (ANZGOG). As the leading research organization in Australia and New Zealand, our mission is simple: Advancing Research, Saving Lives.
ANZGOG brings together over 1,500 members across Australia and New Zealand who are experts in gynaecological cancer, including surgical and medical oncologists, researchers, and allied health professionals. Just as importantly, we collaborate with those who have lived experience—survivors, carers, and advocates—whose insights help shape and strengthen our research. These members work together to bring the best treatments possible to women with gynaecological cancer.
Together, we’re driving breakthroughs in treatment and improving outcomes for women.
Multidisciplinary
We bring together the brightest minds in gynaecological oncology, from a range of specialities and disciplines, to create research of the highest quality for women.
Community Input
People with a lived experience help shape our research at every stage of the research development process, ensuring its relevancy and enabling them to have a voice.
Equitable Access
We are inclusive and strive to enable access to and benefit from our research for all, ensuring that our research engages women from a range of diverse backgrounds and regional/rural areas.
Every Woman’s Cancer is Unique – So is Our Research
Gynaecological cancers are complex, and no two women experience them the same way. Research over the past decade has revealed that these cancers behave differently at a molecular level, driven by unique genetic expressions.
At ANZGOG, we recognise this individuality. Our research is focused on developing targeted treatments that move beyond the outdated, one-size-fits-all approach, because precision leads to better outcomes.
“Progress only comes through research… we can’t make progress or change outcomes unless we undertake clinical trial research”
Professor Michael Friedlander AM
Medical Oncologist, ANZGOG Co-founder
ANZGOG members work together to drive innovative research that transforms treatment pathways and improves outcomes for women. Through our clinical trials, women diagnosed with gynaecological cancer gain access to the latest, cutting-edge treatments from around the world.
With 80 research-ready sites across Australia and New Zealand—spanning both metropolitan and regional centres—we ensure more women have the opportunity to participate in life-changing research. As part of a global collaboration, we share knowledge and trial breakthroughs to accelerate progress and avoid duplication.
“ANZGOG’s extensive collaborations across our multidisciplinary membership give us critical reach and power. Put simply, our collaborative approach can be transformative. We are committed to realising this potential by continually building support for discovery research, clinical trials and supportive care reasearch needed to improve outcomes for women with gynaecological cancers and their families.”
Professor Clare Scott AM
ANZGOG Chair 2022-2026
ANZGOG’s Latest Trials
ANZGOG trials are led by our members, with some developed locally and others run as part of international collaborations, where ANZGOG leads the Australian and New Zealand operations. This allows ANZGOG to offer a wide range of trials and fast-track new treatments for women.
For more information on ANZGOG’s trials, please contact us or visit our website. Always speak to your oncologist for more information on how to participate in a clinical trial.
IGNITE
IGNITE is testing how effective adavosertib treatment is for patients with relapsed high grade serous or endometrioid ovarian cancer with particular genetic faults, which alter how tumour cells respond to treatment.
ADELE
ADELE is a randomised phase 2 trial testing the effect of adjuvant tislelizumab plus chemotherapy after post-operative pelvic chemoradiation in high risk endometrial cancer.
EPOCH
EPOCH is seeking to improve outcomes in women with tubo-ovarian or uterine carcinosarcoma by providing patients with access to a treatment that offers a greater degree of clinical benefit compared to currently available standard chemotherapeutic options.
“I am alive because of a clinical trial. Ther’s no other way to make change or drive improvements, Being part of a trial can give hope along with the reward of knowing you’re contributing to something bigger.”
Kristin, diagnosed with ovarian cancer 2012
STS volunteer
Groundbreaking research is costly and critically underfunded in Australia. We rely on generous donations to drive the next breakthroughs in treatment and improve survival rates for women facing these cancers. You can help us change the future of gynaecological cancer treatment.
Our Research Programs
ANZGOG focuses on key research areas to advance treatment and care for women affected by gynaecological cancers:
Patient Referral Networks Project
The Patient Referral Networks Project aims to build regional and rural capacity for gynaecological cancer research, enabling patients in these areas to access ANZGOG research. The project aims to connect regional sites with metropolitan trial units, promote the use of teletrials in ANZGOG research, and understand and address barriers to trial participation for underserved population groups.
Rose Varga's Legacy - Saving Women's Lives
Rose Varga lived life on her own terms, traveling Australia in a Kombi van with her husband, Des, after arriving as refugees from Hungary. She understood the urgency of research into ovarian cancer. As a clinical trial participant herself, Rose saw firsthand how research could change lives.
It was her belief in the power of clinical trials that led her to leave a gift in her Will—one that helped make the OASIS Initiative a reality.
OASIS, the Ovarian cancer Alliance for SIgnal-Seeking clinical trials, is a world-class collaborative research program. These trials act as scouting parties, mapping the terrain ahead and guiding researchers toward better treatments. Thanks to Rose’s generosity, OASIS is now driving forward a series of trials that personalise treatment for women affected by ovarian cancer—continuing the impact she believed in.
Like Rose, you can create a lasting legacy that drives life-changing research and gives hope to future generations. A gift in your Will can help shape the future of gynaecological cancer treatment.
To find out more, please click here, or get in touch with:
Karen Livingstone AM
Manager, Advocacy & Development | ANZGOG
E: karen.livingstone@anzgog.org.au
M: +61438 11 55 24
Get Involved – Make a Difference
Your support can help drive life-saving research and improve outcomes for women with gynaecological cancer. Here’s how you can make an impact:
KAREN LIVINGSTONE AM – ANZGOG Manager, Advocacy and Development
Following the death of her mother and aunt from ovarian cancer, Karen Livingstone AM has been an advocate, pushing for increased awareness, and funding for research to improve survival for women. Karen also subsequently discovered that she carries the BRCA2 gene mutation, which puts her and her family at a higher population risk.
In 2001, Karen along with a small, committed group founded the ovarian cancer consumer movement in Australia to ensure no woman would travel alone after a diagnosis.
She was invited to join the ANZGOG Board as an inaugural consumer director and served between 2008-2017.
In 2018, Karen was a Finalist in the Victorian, Australian of the Year, and in 2019, Karen was awarded a Member of the Order of Australia (AM) for significant service to community health as an advocate for ovarian cancer research.
Karen Livingstone AM is the Manager of Advocacy and Development raising vital funds to support ANZGOG’s research and education programs Advancing Research, saving lives.
“We need to invest more in medical research, and we need to act more in prevention. They’re the things that will make a difference. So many inroads have been undertaken into personalised treatments and that’s going to be a major change agent for improved survival and better quality of life for women with gynaecological cancer.”
